

RISE

Representation in
Clinical Research



... is a team at Amgen that is dedicated to improving the diversity and representation of participants in the company's clinical trials

BACKGROUND
ON CLINICAL
TRIAL DIVERSITY



WHY IT
MATTERS



COMMITMENT
TO CHANGE




STEPS TO
BUILD ON



“ We are dedicated to the development of new drugs based on clinical trials, conducted without bias, and with representation of all patients who are afflicted with the disease we are seeking to treat. ”

– Ponda Motsepe-Ditshego, MD, Vice President, Global Medical Therapeutic Area Head, Inflammation & Head of Representation in Clinical Research

Background on Clinical Trial Diversity



Black/African Americans make up over 13% of the U.S. population, but only **7%** of clinical trial participants.^{2,3}

Hispanics/Latinos represent over 18% of the U.S. population, but only **11%** of clinical trial participants.^{2,4}

Asian Americans make up 6% of the U.S. population, but make up only **1.7%** of participants for drugs for which at least 70% of trials were conducted in the U.S.⁵



NEXT



Background on Clinical Trial Diversity

Why It Matters


Our Commitment to Change

Steps to Build On

Clinical Trial Diversity Has Not Kept Pace With the Incidence of Major Diseases Among Population Groups


All racial and ethnic minority groups have been underrepresented in clinical trials vs. the proportion of the general population that they represent.

30% MORE LIKELY TO DIE FROM HEART DISEASE^{8,9}



LEARN MORE +

4% OF PARTICIPANTS WERE BLACK/AFRICAN AMERICAN^{10,11}




LEARN MORE +

2x MORE LIKELY TO SUFFER FROM SEVERE ASTHMA^{8,9}



LEARN MORE +



Background on Clinical Trial Diversity

Why It Matters


Our Commitment to Change

Steps to Build On






30% MORE LIKELY TO DIE FROM HEART DISEASE



Black/African Americans are 30% more likely to die from heart disease than non-Hispanic Whites, but they make up only **2.5% of cardiovascular disease clinical trials.**^{8,9}




4% OF PARTICIPANTS WERE BLACK/AFRICAN AMERICAN



Black/African Americans bear a disproportionate share of the cancer burden, having the highest death rate and the lowest survival rate of any racial or ethnic group in the U.S. for most cancers.¹⁰ Yet according to the FDA, in 2019 alone, of the 3,593 participants in oncology trials globally, **73% were White, 18% were Asian, 4% were Black or African American, 5% were Hispanic.**^{10,11}




2x MORE LIKELY TO SUFFER
FROM SEVERE ASTHMA




Black/African American and Hispanic patients suffer disproportionately from severe asthma. However, they are often underrepresented within clinical trials of asthma therapies.^{8,9}

Click on each  icon to learn more


PARTICIPANTS IN CLINICAL TRIALS



CONSEQUENCES OF UNDER-REPRESENTATION



EQUITABLE ACCESS TO CLINICAL TRIALS



RELEVANCE OF RACIAL AND/OR ETHNIC BACKGROUND



Background on Clinical Trial Diversity


Why It Matters

Our Commitment to Change


Steps to Build On

Click on each  icon to learn more


Clinical trials are a critical part of developing a new medicine. Volunteer participants make a vital contribution to research and generate valuable information.



When some groups are underrepresented in clinical trials for new medicines, there is a risk of collecting insufficient data to assess their effectiveness or safety in those populations.¹³



Clinical research contributes to scientific knowledge for treatment options that may potentially benefit patients, physicians, and the broader research community in the future. Equitable access to clinical trials is integral to achieving health equity.



Racial and/or ethnic background, in combination with other interdependent factors including social determinants and genetics, can contribute to differences in drug exposure or response.¹⁴



Background on Clinical Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On

Commitment to Change



RISE is working to exceed industry standards for clinical trial diversity and representation and to help Amgen develop new medicines studied in participants who better reflect the populations impacted by certain diseases or conditions.

“ We aim to improve clinical trial diversity so that populations of certain races, ethnicities, and geographies will no longer be underrepresented, undertreated, and understudied. ”

– Jude Ngang, PharmD, Executive Director, Representation in Clinical Research for Amgen



NEXT

“ When we raise the health of those who have been underrepresented for far too long, we raise the health of everyone. ”

– Racquel Racadio, MPH, Director, Representation in Clinical Research for Amgen




Background on Clinical Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On

Amgen Is Driven by 6 Pillars



EVOLVE

PARTNER

RESEARCH

COMMUNICATE

ENHANCE

COLLABORATE

LEARN MORE +




Background on Clinical Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On

Amgen Is Driven by 6 Pillars



PREV

Evolve the way we design and run clinical trials, focusing on people who have been historically excluded from clinical research

Partner with clinical trial investigators who are representative of the participants they are aiming to recruit

Bring the research directly to the communities where people live and work

Change how researchers communicate with patients, caregivers, and providers

Enhance precision medicine awareness and improve genetic diversity in translational science

Collaborate with national and community organizations

COLLAPSE —




Background on Clinical Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On



STEP ONE

STEP TWO

STEP THREE

STEP FOUR

STEP FIVE

Slide the flag
along to
learn more

2001

Amgen created
ABEN (Amgen
Black Employee
Network)




Background on Clinical
Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On



Slide the flag
along to
learn more

2001
Amgen created
ABEN (Amgen
Black Employee
Network)

2018
Amgen donated \$2
million to Lazarex
Cancer Foundation
Improving Patient
Access to Cancer
Clinical Trials program,
resulting in 50%
minority participation.¹⁵

2020
Amgen announced
a \$100 million
commitment to
improve patient
access to cancer
clinical trials.

2021
Amgen announced
a \$100 million
commitment to
improve patient
access to cancer
clinical trials.

2022
Amgen announced
a \$100 million
commitment to
improve patient
access to cancer
clinical trials.




Background on Clinical
Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On

Steps to Build On



Slide the flag along to learn more

Five blue blocks of increasing height, each representing a milestone. The first block is for 2001, the second for 2018, and the third for 2020. The fourth and fifth blocks are empty.

Year	Event
2001	Amgen created ABEN (Amgen Black Employee Network)
2018	Amgen donated \$2 million to Lazarex Cancer Foundation Improving Patient Access to Cancer Clinical Trials program, resulting in 50% minority participation. ¹⁵
2020	RISE launches with a full-time, dedicated team




Background on Clinical Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On

Steps to Build On



Slide the flag along to learn more

2001
Amgen created ABEN (Amgen Black Employee Network)

2018
Amgen donated \$2 million to Lazarex Cancer Foundation Improving Patient Access to Cancer Clinical Trials program, resulting in 50% minority participation.¹⁵

2020
RISE launches with a full-time, dedicated team

2021
Amgen stands with PhRMA to focus on building trust and acknowledging the historic mistrust of clinical trials within Black and Brown communities, reducing barriers to clinical trial access, using real-world data to enhance information on diverse populations beyond product approval and enhancing information about diversity and inclusion in clinical trial participation.




Background on Clinical Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On

Steps to Build On



Slide the flag
along to
learn more

2001
Amgen created ABEN (Amgen Black Employee Network)

2018
Amgen donated \$2 million to Lazarex Cancer Foundation Improving Patient Access to Cancer Clinical Trials program, resulting in 50% minority participation.¹⁵

2020
RISE launches with a full-time, dedicated team

2021
Amgen stands with PhRMA to focus on building trust and acknowledging the historic mistrust of clinical trials within Black and Brown communities, reducing barriers to clinical trial access, using real-world data to enhance information on diverse populations beyond product approval and enhancing information about diversity and inclusion in clinical trial participation.

2023
The Robert A. Winn Diversity in Clinical Trials Award Program was established by BMS to promote diversity in clinical trials and evolve the environment for clinical research. Amgen has pledged a total of \$8 million dollars to the program for a four-year period. With the help of this donation, the program will be able to contact more doctors and medical students, furthering its mission to increase access to clinical trials for underrepresented patient groups in American communities. Amgen has also joined Novartis in its Beacon of Hope initiative to create clinical trial centers of excellence at HBCUs to increase enrollment of underrepresented populations to better represent disease demographics.



Background on Clinical Trial Diversity

Why It Matters

Our Commitment to Change

Steps to Build On



References

1. Board of Editors. Clinical trials need more diversity. *Scientific American*. Sept. 1, 2018. Available at: <https://www.scientificamerican.com/article/clinical-trials-have-far-too-little-racial-and-ethnic-diversity/>.
2. United States Census Bureau. QuickFacts: United States, Population estimates V2019. Available at: <https://www.census.gov/quickfacts/fact/table/US/PST045219>.
U.S. Food and Drug Administration. 2015–2019 Drug trials snapshots report: Five-year summary and analysis of clinical trial participation and demographics. Available at: <https://www.fda.gov/media/143592/download>
3. Coakley, M, Fadiran, EO, Parrish, LJ, et al. Dialogues on diversifying clinical trials: Successful strategies for engaging women and minorities in clinical trials. *Journal of Women's Health*. 2012;21(7):713–716. Available at <http://doi.org/10.1089/jwh.2012.3733>.
5. Chen C, Wong W. Black patients miss out on promising cancer drugs. *ProPublica*. Published September. 19, 2018. Available at: <https://www.propublica.org/article/black-patients-miss-out-on-promising-cancer-drugs>
6. Terry M. Pushing for more ethnic and racial diversity in clinical trials. *BioSpace.com*. Published June 12, 2020. Available at: <https://www.biospace.com/article/pushing-for-more-ethnic-and-racial-diversity-in-clinical-trials>.
7. Vigil D, Sinaii N, Karp B. American Indian and Alaska Native enrollment in clinical studies in the National Institutes of Health's intramural research program. *Ethics & Human Research*. Published May 21, 2021. Available at: <https://doi.org/10.1002/eahr.500090>.
8. Murphy SL, Xu J, Kochanek KD, et al. Deaths: final data for 2018. *National Vital Statistics Reports*. 2021;69(13). Published January 12, 2021. Available at: <https://www.cdc.gov/nchs/data/nvsr/nvsr69/nvsr69-13-508.pdf>
9. U.S. Food & Drug Administration. Global participation in clinical trials Report, 2015–2016. Published July 2017. Available at: <https://www.fda.gov/media/106725/download>
10. DeSantis CE, Miller KD, Sauer, AG, et al. Cancer statistics for African Americans 2019. *American Cancer Society Journals*. 2019;69(3). Available at: <https://doi.org/10.3322/caac.21555>.
11. U.S. Food and Drug Administration. Drug trials snapshots summary report, 2019. Published January 2020. Available at: <https://www.fda.gov/media/135337/download>.
12. Kesh S, Jones B. Racial/ethnic demographics of participants in clinical trials of biologics used for asthma. [abstract taken from *Ann Allergy Asthma Immunol*. 2018; S22–S62]. Available at: [https://www.annallergy.org/article/S1081-1206\(18\)30877-9/pdf](https://www.annallergy.org/article/S1081-1206(18)30877-9/pdf)
13. Haque W, Ahmadzada M. Lack of diversity in clinical trials: the problem and potential solutions. *Hopkins Biotech Network*. Published November 20, 2020. Available at: <https://hopkinsbio.org/academic/diversity-in-clinical-trials/>
14. Ramamoorthy A, Pacanowski MA, Bull J, et al. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. *Clinical Pharmacology & Therapeutics*. 2015;97(3):263–73. doi: 10.1002/cpt.61. Epub 2015 Jan 20. PMID: 25669658.
15. Lazarex Foundation. Disrupting the system II: fixing the cancer clinical trial conundrum. *Lazarex.org*. Accessed on August 30, 2021. Available at <https://lazarex.org/disrupting-the-system-II/>.